Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RN026
- Development stage
- Preclinical
- Lead developer
- Rona Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RN026 is an investigational RNA interference (RNAi) therapeutic developed by Rona Therapeutics. It targets lipoprotein(a) [Lp(a)], a well-established risk factor for cardiovascular diseases. The drug is designed to lower Lp(a) levels in the blood, potentially reducing the risk of atherosclerotic cardiovascular disease (ASCVD), aortic stenosis, and other related conditions. RN026 utilizes RNAi technology to silence the gene responsible for producing apolipoprotein(a), thereby decreasing circulating Lp(a). Early clinical data suggest that RN026 may enable infrequent dosing, possibly as little as once per year[1][2].
02
Targets
LPA (Lysophosphatidic acid)
Beyond the preview
Go deeper on RN026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RN026.